Compare CNTB & HNVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTB | HNVR |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 147.6M |
| IPO Year | 2020 | 2022 |
| Metric | CNTB | HNVR |
|---|---|---|
| Price | $3.13 | $21.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $8.50 | ★ $24.50 |
| AVG Volume (30 Days) | ★ 131.3K | 4.3K |
| Earning Date | 05-14-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.85% |
| EPS Growth | ★ 75.22 | N/A |
| EPS | N/A | ★ 1.00 |
| Revenue | ★ $26,033,000.00 | N/A |
| Revenue This Year | N/A | $28.03 |
| Revenue Next Year | $17,706.72 | $8.02 |
| P/E Ratio | ★ N/A | $21.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $18.31 |
| 52 Week High | $3.28 | $24.36 |
| Indicator | CNTB | HNVR |
|---|---|---|
| Relative Strength Index (RSI) | 64.39 | 56.38 |
| Support Level | $2.09 | $21.60 |
| Resistance Level | $3.23 | $22.41 |
| Average True Range (ATR) | 0.21 | 0.52 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 85.53 | 96.13 |
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.